**Core Concept**
The International Prognostic Index (IPI) is a widely used tool for assessing the prognosis of patients with aggressive non-Hodgkin lymphoma (NHL). It takes into account several clinical and laboratory parameters to predict the likelihood of disease progression and overall survival.

**Why the Correct Answer is Right**
The IPI includes five key prognostic factors: age, Ann Arbor stage, performance status, serum lactate dehydrogenase (LDH) level, and the number of extranodal sites involved. The presence of extranodal sites is a significant predictor of poor prognosis, as it indicates the spread of lymphoma beyond the lymph nodes. This factor helps clinicians to stratify patients according to their risk of disease progression and guide treatment decisions accordingly.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because age is a key component of the IPI, with older patients generally having a poorer prognosis.
* **Option B:** This option is incorrect because Ann Arbor stage is also a crucial factor in the IPI, with advanced stages (III-IV) associated with a higher risk of disease progression.
* **Option C:** This option is incorrect because performance status is an essential component of the IPI, with patients with poor performance status (ECOG 2-4) having a poorer prognosis.
* **Option D:** This option is incorrect because serum lactate dehydrogenase (LDH) level is a key prognostic factor in the IPI, with elevated LDH levels associated with a higher risk of disease progression.

**Clinical Pearl / High-Yield Fact**
The IPI is widely used in clinical practice to predict the prognosis of patients with aggressive NHL. A high IPI score (2-5) indicates a poorer prognosis and may guide the use of more intensive chemotherapy regimens or the inclusion of rituximab in treatment protocols.

**Correct Answer: D.**